WilmerHale provides legal representation across a comprehensive range of practice areas critical to the success of its clients. With a staunch commitment to public service, the firm is a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia.
These are tough times in the biotech and pharmaceutical industries: Funding is drying up,
investors are fleeing the space, the IPO door is pretty firmly shut, valuations are dropping,
activists are lurking and the headlines are anything but kind.
United StatesFood, Drugs, Healthcare, Life Sciences
These are tough times in the biotech and pharmaceutical
industries: Funding is drying up, investors are fleeing the space,
the IPO door is pretty firmly shut, valuations are dropping,
activists are lurking and the headlines are anything but kind. But
when the going gets tough, the tough consider strategic
alternatives.
WilmerHale's Life Sciences Group Co-Chairs Belinda Juran and
Stuart Falber were interviewed by Med City News, March 4,
2016
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
